RARE DISEASE
Rare dystonia
Rare dystonia
Rare dystonia
Synonyms: Rare dystonic disorder
Synonyms: Rare dystonic disorder
Synonyms: Rare dystonic disorder
Drug discovery
1
drug
With orphan designation
Overview
Rare dystonias encompass genetically inherited and idiopathic movement disorders characterized by sustained or intermittent involuntary muscle contractions causing abnormal postures, tremors, and functional impairment. These disorders exhibit phenotypic variability, with focal (e.g., cervical dystonia, writer's cramp) and generalized forms, often presenting with pain, psychiatric comorbidities, and progressive disability [1][6][12].
Population
Prevalence ranges from 16.43/100,000 for primary dystonia to 1/200,000–330,000 for early-onset generalized forms in Europe [4][14]
Higher incidence in Ashkenazi Jewish populations (1/3,000–9,000) due to TOR1A founder mutations [4][16]
Adult-onset focal dystonia (e.g., cervical dystonia, blepharospasm) is most common, accounting for ~70% of cases [12][17]
Burden
Functional impact: 28.3% of focal dystonia patients experience symptom spread, worsening disability [1][12]
Psychiatric comorbidity: 42.5% report depression/anxiety, correlating with symptom severity [8][11][19]
Economic: High costs from repeated botulinum toxin regimens ($1,800–$3,800 annual) and DBS surgery ($50,000–$100,000) [8][10]
Therapies
First-line: Botulinum toxin injections for focal/segmental dystonia [3][8][13]
Oral agents: Trihexyphenidyl (anticholinergic) and levodopa (for dopa-responsive dystonia) [6][18][19]
Advanced: Deep brain stimulation (GPi target) for medically refractory generalized dystonia, particularly in DYT1 carriers [4][8][11]
Categories: rare neurological diseases
Research Papers
378 drug discovery papers about Rare dystonia, with 2 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
378 drug discovery papers about Rare dystonia, with 2 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-21 | Isolated Lingual Dystonia: A Rare Tardive Manifestation of Amisulpride
Aims: To describe a rare case of isolated lingual tardive dyskinesia associated with prolonged low-dose amisulpride therapy and to emphasise the importance of early recognition and treatment. Presentation of Case: A 72-year-old woman with bipolar I disorder developed progressive dysarthria, dysphagia, and involuntary choreiform tongue movements after approximately 13 months of amisulpride therapy, initiated at 50 mg/day and titrated to 150 mg/day. Neurological examination showed continuous lingual movements with intermittent dystonic posturing, without limb involvement or other focal neurological abnormalities. Brain magnetic resonance imaging demonstrated only mild age-related cerebral atrophy, and routine laboratory investigations were within normal limits. Alternative structural, metabolic, seizure-related, and neurodegenerative causes were considered and excluded clinically. The Naranjo score was 6, and the WHO-UMC assessment classified the reaction as probable/likely. Amisulpride was discontinued, and tetrabenazine was initiated at 12.5 mg each morning and 25 mg each night. After six weeks, tongue movements and speech improved markedly, permitting dose reduction to 12.5 mg twice daily. Psychiatric stability was maintained with clozapine and sodium valproate/valproic acid. Discussion: The delayed onset, temporal relationship to prolonged dopamine receptor blockade, absence of an alternative cause, and improvement after withdrawal supported a tardive drug-induced movement disorder. Conclusion: Isolated lingual dystonia may occur during long-term low-dose amisulpride therapy. Regular movement assessment and prompt treatment modification may reduce functional impairment.
2026-07-16 | Laryngeal dystonia: a comprehensive review of aetiology, clinical presentation, diagnosis, and treatment approaches.
Laryngeal dystonia (LD), also known as spasmodic dysphonia, is a rare voice production pathology manifested as focal muscle dystonia. The aim of this review is to synthesize current evidence on its aetiology, clinical presentation, diagnostic approach, and available treatment options, while identifying existing knowledge gaps to guide clinical decision-making and future research. A structured literature review was conducted using peer-reviewed articles from medical databases (e.g., PubMed, Google Scholars). Inclusion criteria comprised studies published in English within the last 20 years, focusing on LD aetiology, clinical features, diagnosis, or treatment. Both observational studies and clinical trials were included. Exclusion criteria involved case reports with limited applicability, non-English publications, and studies lacking clear diagnostic criteria or therapeutic outcomes. Primarily an idiopathic disorder, there is evidence suggesting a neurogenic origin involving basal ganglia dysfunction in LD. Clinically, LD manifests as task-specific voice disturbances, affecting most commonly the adductor muscles (strained voice) or the abductor muscles (breathy voice). Diagnosis is mainly clinical, but supported by laryngoscopic findings and other multidisciplinary evaluation. The gold standard treatment remains botulinum toxin injection, providing symptomatic relief, while voice therapy and, in selected cases, surgical interventions offer adjunctive benefits. LD is a neurological voice disorder which requires a high index of suspicion for diagnosis. Individualized treatment, particularly with botulinum toxin, and early recognition, significantly improve patient outcomes. Further research is needed to clarify pathophysiological mechanisms and optimize long-term management strategies.
2026-07-09 | Relative Efficacy of Self-Managed Caffeine Supplementation in Maintaining Daily Activity in a Patient with ADCY5-Related Dyskinesia: A Case Report.
ADCY5-related dyskinesia is an autosomal dominant movement disorder with limited treatment options because many standard medications are ineffective. Caffeine has shown efficacy in ADCY5-related dyskinesia as an adenosine A2A receptor antagonist, but optimal dosing remains uncertain. We report a 24-year-old woman with paroxysmal dyskinesia since early childhood, consisting of chorea, dystonia, and myoclonus upon waking. More than 15 medications failed. Whole-exome sequencing identified a mosaic ADCY5 variant (p.R418Q, 7% variant allele frequency). Caffeine escalation from 100 to 600 mg worsened symptoms. Four months later, she found that unsweetened canned coffee containing approximately 100 mg of caffeine per can, taken 1-3 times daily, reduced her symptoms and helped her maintain daily employment. In a self-controlled analysis of 39 coffee-intake events, dyskinesia episodes during the 6 h after coffee intake were significantly fewer than during the preceding 6 h (p = 0.002). This case demonstrates successful symptom control in ADCY5-related dyskinesia using patient-directed, low-dose caffeine therapy. The striking response suggests a narrow therapeutic window for caffeine in this condition and that patient self-titration may be valuable in optimizing treatment response.
2026-07-02 | Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report.
Pathogenic loss-of-function variants in the KMT2B gene cause a rare autosomal dominant disorder with two major phenotypes: KMT2B-related dystonia (DYT-KMT2B) and KMT2B-related neurodevelopmental disorder (KMT2B-NDD). Central precocious puberty (CPP) has been documented as a comorbidity in patients with DYT-KMT2B, but has not been reported as the primary clinical manifestation of the disorder in patients without dystonia. Deletions or pathogenic variants in the STS gene cause X-linked ichthyosis (XLI). Concurrent KMT2B and STS alterations have not been well characterised, and GnRH analogue therapy for CPP in KMT2B-related disorders has not been previously described. An 8-year-10-month-old male presented with a 1-2-year history of progressive increase in penile length and girth. Physical examination revealed distinctive craniofacial dysmorphism, classic ichthyotic scaling, pubertal changes consistent with precocious puberty, and normal muscle tone without dystonic features. Biochemical testing confirmed markedly elevated serum total testosterone, a positive gonadotropin-releasing hormone (GnRH) stimulation test consistent with CPP, and bone age advanced by 1.2 years relative to chronological age. Neurocognitive assessment identified mild intellectual disability. Family-based whole-exome sequencing and copy number variation (CNV) analysis identified a de novo heterozygous pathogenic nonsense variant in KMT2B (NM_014727.3: c.4213del, p.Leu1405Ter) and a hemizygous pathogenic full-coding deletion of STS. The patient was treated with leuprorelin acetate for CPP and topical emollients for XLI. At 3-month follow-up, physical signs of puberty remained stable. GnRHa stimulation test showed indicating but incomplete suppression of the hypothalamic-pituitary-gonadal axis. The ichthyotic skin lesions improved markedly with topical therapy. The leuprorelin acetate dose was subsequently increased. The patient is continuing on the current regimen with close monitoring. Precocious puberty has been reported in eleven patients with KMT2B-related dystonia. This case documents the co-occurrence of a KMT2B-related disorder and XLI in a patient, and provides documentation of GnRH analogue therapy and structured endocrine follow-up for CPP in this population. KMT2B haploinsufficiency may contribute to premature activation of the hypothalamic-pituitary-gonadal axis through disruption of ERα-mediated transcriptional regulation and altered epigenetic programming at key hypothalamic developmental genes. Clinically, children with KMT2B-related disorders should undergo comprehensive endocrine assessment to facilitate early diagnosis and timely intervention.
2026-06-26 | Clinical and Genetic Spectrum of ANO3-Related Dystonia with Treatment Responses in a Chinese Cohort.
Background: Variants in anoctamin 3 (ANO3) are linked to autosomal dominant dystonia, commonly known as DYT-ANO3 (OMIM: #615034). While craniocervical dystonia constitutes the most frequently observed phenotype, its clinical manifestations display significant heterogeneity. Nevertheless, the data concerning the genetic characteristics, clinical features, and therapeutic outcomes of ANO3-related dystonia within Asian populations remain scarce. Methods: Whole-exome sequencing was conducted on 661 Chinese patients, comprising 356 individuals with dystonia and 305 individuals with non-dystonic movement disorders who served as an internal disease-control cohort. Candidate ANO3 variants were evaluated based on population frequency, predicted deleteriousness, ACMG criteria, and aggregate frequency analyses. A retrospective review was performed of clinical features and treatment responses. Results: Fifteen rare ANO3 missense variants were identified in 16 patients with dystonia and one non-dystonic individual, including one pathogenic variant, six likely pathogenic variants, and nine previously unreported variants. The rare ANO3 variants were significantly enriched in the dystonia cohort compared with the controls. ANO3-related dystonia exhibited broad clinical heterogeneity, with frequent cervical involvement (62.5%) and tremulous features (75%), and occasionally extended beyond classical isolated dystonia. Oral medication and botulinum toxin showed variable benefit, whereas deep brain stimulation was associated with marked improvement in selected medically refractory patients. Conclusions: This study broadens the genetic and clinical spectrum of ANO3-related movement disorders in a Chinese cohort. The findings support substantial clinical heterogeneity in DYT-ANO3 and suggest that deep brain stimulation, especially STN-DBS, may be considered in selected refractory cases, although further studies are needed.
2026-07-21 | Isolated Lingual Dystonia: A Rare Tardive Manifestation of Amisulpride
Aims: To describe a rare case of isolated lingual tardive dyskinesia associated with prolonged low-dose amisulpride therapy and to emphasise the importance of early recognition and treatment. Presentation of Case: A 72-year-old woman with bipolar I disorder developed progressive dysarthria, dysphagia, and involuntary choreiform tongue movements after approximately 13 months of amisulpride therapy, initiated at 50 mg/day and titrated to 150 mg/day. Neurological examination showed continuous lingual movements with intermittent dystonic posturing, without limb involvement or other focal neurological abnormalities. Brain magnetic resonance imaging demonstrated only mild age-related cerebral atrophy, and routine laboratory investigations were within normal limits. Alternative structural, metabolic, seizure-related, and neurodegenerative causes were considered and excluded clinically. The Naranjo score was 6, and the WHO-UMC assessment classified the reaction as probable/likely. Amisulpride was discontinued, and tetrabenazine was initiated at 12.5 mg each morning and 25 mg each night. After six weeks, tongue movements and speech improved markedly, permitting dose reduction to 12.5 mg twice daily. Psychiatric stability was maintained with clozapine and sodium valproate/valproic acid. Discussion: The delayed onset, temporal relationship to prolonged dopamine receptor blockade, absence of an alternative cause, and improvement after withdrawal supported a tardive drug-induced movement disorder. Conclusion: Isolated lingual dystonia may occur during long-term low-dose amisulpride therapy. Regular movement assessment and prompt treatment modification may reduce functional impairment.
2026-07-16 | Laryngeal dystonia: a comprehensive review of aetiology, clinical presentation, diagnosis, and treatment approaches.
Laryngeal dystonia (LD), also known as spasmodic dysphonia, is a rare voice production pathology manifested as focal muscle dystonia. The aim of this review is to synthesize current evidence on its aetiology, clinical presentation, diagnostic approach, and available treatment options, while identifying existing knowledge gaps to guide clinical decision-making and future research. A structured literature review was conducted using peer-reviewed articles from medical databases (e.g., PubMed, Google Scholars). Inclusion criteria comprised studies published in English within the last 20 years, focusing on LD aetiology, clinical features, diagnosis, or treatment. Both observational studies and clinical trials were included. Exclusion criteria involved case reports with limited applicability, non-English publications, and studies lacking clear diagnostic criteria or therapeutic outcomes. Primarily an idiopathic disorder, there is evidence suggesting a neurogenic origin involving basal ganglia dysfunction in LD. Clinically, LD manifests as task-specific voice disturbances, affecting most commonly the adductor muscles (strained voice) or the abductor muscles (breathy voice). Diagnosis is mainly clinical, but supported by laryngoscopic findings and other multidisciplinary evaluation. The gold standard treatment remains botulinum toxin injection, providing symptomatic relief, while voice therapy and, in selected cases, surgical interventions offer adjunctive benefits. LD is a neurological voice disorder which requires a high index of suspicion for diagnosis. Individualized treatment, particularly with botulinum toxin, and early recognition, significantly improve patient outcomes. Further research is needed to clarify pathophysiological mechanisms and optimize long-term management strategies.
2026-07-09 | Relative Efficacy of Self-Managed Caffeine Supplementation in Maintaining Daily Activity in a Patient with ADCY5-Related Dyskinesia: A Case Report.
ADCY5-related dyskinesia is an autosomal dominant movement disorder with limited treatment options because many standard medications are ineffective. Caffeine has shown efficacy in ADCY5-related dyskinesia as an adenosine A2A receptor antagonist, but optimal dosing remains uncertain. We report a 24-year-old woman with paroxysmal dyskinesia since early childhood, consisting of chorea, dystonia, and myoclonus upon waking. More than 15 medications failed. Whole-exome sequencing identified a mosaic ADCY5 variant (p.R418Q, 7% variant allele frequency). Caffeine escalation from 100 to 600 mg worsened symptoms. Four months later, she found that unsweetened canned coffee containing approximately 100 mg of caffeine per can, taken 1-3 times daily, reduced her symptoms and helped her maintain daily employment. In a self-controlled analysis of 39 coffee-intake events, dyskinesia episodes during the 6 h after coffee intake were significantly fewer than during the preceding 6 h (p = 0.002). This case demonstrates successful symptom control in ADCY5-related dyskinesia using patient-directed, low-dose caffeine therapy. The striking response suggests a narrow therapeutic window for caffeine in this condition and that patient self-titration may be valuable in optimizing treatment response.
2026-07-02 | Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report.
Pathogenic loss-of-function variants in the KMT2B gene cause a rare autosomal dominant disorder with two major phenotypes: KMT2B-related dystonia (DYT-KMT2B) and KMT2B-related neurodevelopmental disorder (KMT2B-NDD). Central precocious puberty (CPP) has been documented as a comorbidity in patients with DYT-KMT2B, but has not been reported as the primary clinical manifestation of the disorder in patients without dystonia. Deletions or pathogenic variants in the STS gene cause X-linked ichthyosis (XLI). Concurrent KMT2B and STS alterations have not been well characterised, and GnRH analogue therapy for CPP in KMT2B-related disorders has not been previously described. An 8-year-10-month-old male presented with a 1-2-year history of progressive increase in penile length and girth. Physical examination revealed distinctive craniofacial dysmorphism, classic ichthyotic scaling, pubertal changes consistent with precocious puberty, and normal muscle tone without dystonic features. Biochemical testing confirmed markedly elevated serum total testosterone, a positive gonadotropin-releasing hormone (GnRH) stimulation test consistent with CPP, and bone age advanced by 1.2 years relative to chronological age. Neurocognitive assessment identified mild intellectual disability. Family-based whole-exome sequencing and copy number variation (CNV) analysis identified a de novo heterozygous pathogenic nonsense variant in KMT2B (NM_014727.3: c.4213del, p.Leu1405Ter) and a hemizygous pathogenic full-coding deletion of STS. The patient was treated with leuprorelin acetate for CPP and topical emollients for XLI. At 3-month follow-up, physical signs of puberty remained stable. GnRHa stimulation test showed indicating but incomplete suppression of the hypothalamic-pituitary-gonadal axis. The ichthyotic skin lesions improved markedly with topical therapy. The leuprorelin acetate dose was subsequently increased. The patient is continuing on the current regimen with close monitoring. Precocious puberty has been reported in eleven patients with KMT2B-related dystonia. This case documents the co-occurrence of a KMT2B-related disorder and XLI in a patient, and provides documentation of GnRH analogue therapy and structured endocrine follow-up for CPP in this population. KMT2B haploinsufficiency may contribute to premature activation of the hypothalamic-pituitary-gonadal axis through disruption of ERα-mediated transcriptional regulation and altered epigenetic programming at key hypothalamic developmental genes. Clinically, children with KMT2B-related disorders should undergo comprehensive endocrine assessment to facilitate early diagnosis and timely intervention.
2026-06-26 | Clinical and Genetic Spectrum of ANO3-Related Dystonia with Treatment Responses in a Chinese Cohort.
Background: Variants in anoctamin 3 (ANO3) are linked to autosomal dominant dystonia, commonly known as DYT-ANO3 (OMIM: #615034). While craniocervical dystonia constitutes the most frequently observed phenotype, its clinical manifestations display significant heterogeneity. Nevertheless, the data concerning the genetic characteristics, clinical features, and therapeutic outcomes of ANO3-related dystonia within Asian populations remain scarce. Methods: Whole-exome sequencing was conducted on 661 Chinese patients, comprising 356 individuals with dystonia and 305 individuals with non-dystonic movement disorders who served as an internal disease-control cohort. Candidate ANO3 variants were evaluated based on population frequency, predicted deleteriousness, ACMG criteria, and aggregate frequency analyses. A retrospective review was performed of clinical features and treatment responses. Results: Fifteen rare ANO3 missense variants were identified in 16 patients with dystonia and one non-dystonic individual, including one pathogenic variant, six likely pathogenic variants, and nine previously unreported variants. The rare ANO3 variants were significantly enriched in the dystonia cohort compared with the controls. ANO3-related dystonia exhibited broad clinical heterogeneity, with frequent cervical involvement (62.5%) and tremulous features (75%), and occasionally extended beyond classical isolated dystonia. Oral medication and botulinum toxin showed variable benefit, whereas deep brain stimulation was associated with marked improvement in selected medically refractory patients. Conclusions: This study broadens the genetic and clinical spectrum of ANO3-related movement disorders in a Chinese cohort. The findings support substantial clinical heterogeneity in DYT-ANO3 and suggest that deep brain stimulation, especially STN-DBS, may be considered in selected refractory cases, although further studies are needed.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Rare dystonia.
1 orphan drug designation for Rare dystonia.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
baclofen | small molecules | FDA | 2003-12-02 | — | Medtronic Neurological |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.